AstraZeneca Canada has announced the availability of the Duaklir Genuair aclidinium bromide/formoterol fumarate DPI in Canada for the treatment of COPD. Health Canada issued a Notice of Compliance for Duaklir Genuair on April 2, 2015.
AstraZeneca acquired Canadian rights to Duaklir Genuair from Actavis in February 2015. In Europe, the inhaler was approved for the treatment of COPD in November 2014.
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
